CGTX - Cognition Therapeutics Presents Preclinical Data Identifying Pathways Impacted by Sigma-2 Receptor Modulators in Alzheimer's and Parkinson's Diseases | Benzinga
NEW YORK, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX) is presenting in vivo preclinical results at the Society for Neuroscience's annual meeting illuminating the role of sigma-2 (?-2) receptor modulators, including CT1812, in models of Alzheimer's and Parkinson's diseases.
The effect of two chemically distinct ?-2 receptor modulators in a mouse model of Alzheimer's disease on gene and protein expression are presented. Data shed light on the molecular mechanisms and build upon previous studies in this same mouse model where Cognition's lead candidate, CT1812 was previously shown to decrease binding of A? oligomers to neuronal synapses and ameliorate cognitive deficits.
Separately, work supported by a Michael J. Fox Foundation grant award is presented defining the impact of ?-2 receptor modulators on gene and protein expression. In two different rat models of Parkinson's disease, the same two ?-2 receptor modulators are shown to effect pathways associated with Parkinson's disease, including cell survival, metabolism, autophagy, and protein/lipid transport.
Mary Hamby, Ph.D., Cognition's VP of research, explained, "These findings help to broaden our understanding of the role of the ?-2 receptor in central nervous system diseases, and support continued discovery and development of candidates that modulate this therapeutic target for Alzheimer's disease, dementia with Lewy bodies, and Parkinson's disease."
Poster details:
Title: A transcriptomic analysis to investigate the role of sigma-2 receptor modulators CT1812 and CT2168 in a mouse model of Alzheimer's disease
Authors: Caldwell J, Cho E, Knezovich N, Caggiano AO, Di Caro V, Hamby ME
Session: Nov 15 - Session PSTR527 - Alzheimer's Disease and Dementia: Genomics and Other Omics Approaches
Title: A proteomic analysis to elucidate the role of sigma-2 receptor modulators CT1812 and CT2168 in a mouse model of Alzheimer's disease
Authors: Cho E, Caldwell J, Pandey K, Duong DM, Seyfried NT, Caggiano AO, Di Caro V, Hamby ME
Session: Nov 15 - Session PSTR527 - Alzheimer's Disease and Dementia: Genomics and Other Omics Approaches
Title: Exploratory omics study reveals potential roles of sigma-2 receptor modulators in AAV1/2A53T-aSyn rat model of Parkinson's disease
Authors: Reaver AJ, Lizama BN, Pandey K, Duong DM, Seyfried NT, Caggiano AO, Hamby ME
Session: Nov 14 - ...